- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Duloxetine and gabapentin equally effective in diabetic neuropathy: Study
Jodhpur, India: Both duloxetine and gabapentin are effective for providing symptomatic relief in painful diabetic neuropathy (PDN) patients and had similar efficacy, finds a recent study in the Journal of Diabetes.
Medicines that are sometimes used to treat depression or epilepsy can be effective in some people with neuropathic pain. Two such medications are duloxetine and gabapentin. Sameer Khasbage, All India Institute of Medical Sciences, Jodhpur, India, and colleagues analysed the efficacy and safety of Duloxetine and Gabapentin in painful diabetic neuropathy.
The researchers conducted a randomized, open label, active control for 12 weeks. It included 86 participants who were randomized to receive Gabapentin 300 mg and Duloxetine 60 mg in the ratio 1:1.
The primary efficacy objective was comparison of mean change in Visual Analogue scale (VAS) (0‐100 points) scores between duloxetine and gabapentin. The symptom scores and adverse events were assessed as secondary outcomes.
Key findings of the study include:
- Statistically significant improvement was observed in VAS scores in both Duloxetine group and Gabapentin group at 12 weeks as compared to baseline.
- However, no significant difference in VAS scores between duloxetine and gabapentin.
- Similar improvement in diabetic neuropathy symptom (DNS), diabetic neuropathy examination (DNE) and Neuropathic disability score (NDS) was observed in either group over 12 weeks.
- There were no significant differences in DNS, DNE and NDS scores between the two treatment groups.
- The overall safety evaluation of both Duloxetine and Gabapentin were similar.
- The most common adverse events reported were gastrointestinal.
"Our results indicate that both drugs were effective for the symptomatic relief from PDN and had similar efficacy. Follow‐up of patients was only for 12 weeks and therefore the long‐term efficacy and safety of the study drugs could not be assessed," concluded the authors.
About Duloxetine
Duloxetine is approved by the US Food and Drug Administration for the management of diabetic peripheral neuropathic pain (DPNP). The proposed mechanism of action of duloxetine, an antidepressant, is reuptake inhibition of both serotonin and norepinephrine in the central nervous system, which increases the activity of these neurotransmitters and subsequently reduces the perception of pain by modulating the pain signals.
About Gabapentin
Gabapentin is an anticonvulsant medication used for the treatment of partial seizures, neuropathic pain, hot flashes, and restless legs syndrome. Gabapentin appears to work by altering electrical activity in the brain and influencing the activity of chemicals called neurotransmitters, which send messages between nerve cells. It has shown to provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy.
The study, "A Randomized Control trial of Duloxetine and Gabapentin in Painful Diabetic Neuropathy," is published in the Journal of Diabetes.
DOI: https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13148
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751